Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Experimental drug Ulefnersen shows potential in halting and even reversing symptoms in patients with FUS- Amyotrophic lateral sclerosis (ALS) mutation One patient regained full motor function ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Prescribed use of anti-anxiety drugs, hypnotics and sedatives, or antidepressants was tied to a higher future risk of ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Amyotrophic lateral sclerosis (ALS) is a progressive disease that causes severe weakness due to progressive degeneration of a specific set of motor nerves in the spinal cord. People with ALS will ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, has announced that the USFDA has granted ‘Fast Track ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Amylyx Pharmaceuticals ( NASDAQ: AMLX) said on Tuesday that the U.S. FDA has granted fast track status to its antisense RNA, ...